CN114569633B - 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 - Google Patents

用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 Download PDF

Info

Publication number
CN114569633B
CN114569633B CN202210138407.5A CN202210138407A CN114569633B CN 114569633 B CN114569633 B CN 114569633B CN 202210138407 A CN202210138407 A CN 202210138407A CN 114569633 B CN114569633 B CN 114569633B
Authority
CN
China
Prior art keywords
chelator
intestinal
activated carbon
mice
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202210138407.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114569633A (zh
Inventor
安托尼·斯图尔特·坎贝尔
戴维·H·多纳伯迪昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapy Co
Original Assignee
Axial Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapy Co filed Critical Axial Therapy Co
Priority to CN202210138407.5A priority Critical patent/CN114569633B/zh
Publication of CN114569633A publication Critical patent/CN114569633A/zh
Application granted granted Critical
Publication of CN114569633B publication Critical patent/CN114569633B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202210138407.5A 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂 Expired - Fee Related CN114569633B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210138407.5A CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
CN202210138407.5A CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
CN201880034095.5A CN110944650B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880034095.5A Division CN110944650B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Publications (2)

Publication Number Publication Date
CN114569633A CN114569633A (zh) 2022-06-03
CN114569633B true CN114569633B (zh) 2023-11-17

Family

ID=63677186

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210138407.5A Expired - Fee Related CN114569633B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
CN201880034095.5A Expired - Fee Related CN110944650B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880034095.5A Expired - Fee Related CN110944650B (zh) 2017-03-31 2018-03-31 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂

Country Status (9)

Country Link
US (4) US10617718B2 (https=)
EP (1) EP3600349A4 (https=)
JP (1) JP6978122B2 (https=)
KR (1) KR102328323B1 (https=)
CN (2) CN114569633B (https=)
AU (3) AU2018243836B9 (https=)
BR (1) BR112019020289A2 (https=)
CA (2) CA3095724C (https=)
WO (1) WO2018183986A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6978122B2 (ja) 2017-03-31 2021-12-08 アキシャル セラピューティクス，インク． 自閉症および関連障害の治療および予防のための腸管選択的隔離剤
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
CN114829629A (zh) * 2019-12-19 2022-07-29 希尔氏宠物营养品公司 治疗和降低患上与犬科动物的升高的4-乙基苯基硫酸盐相关的病状的风险的组合物和方法以及鉴定有风险患上此类病状的犬科动物的方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
CN103491949A (zh) * 2011-03-04 2014-01-01 株式会社吴羽 片剂型的口服给药用组合物及其制造方法
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
CN101084206A (zh) * 2004-12-13 2007-12-05 艾尼纳制药公司 作为5ht2c受体调节剂以治疗与其相关病症的n－联芳基和n－芳基杂芳基2－经取代哌嗪衍生物
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012161921A1 (en) * 2011-05-23 2012-11-29 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
US10060932B2 (en) 2013-07-09 2018-08-28 Stemina Biomarker Discovery, Inc. Biomarkers of autism spectrum disorder
JP2016525138A (ja) * 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
JP6978122B2 (ja) 2017-03-31 2021-12-08 アキシャル セラピューティクス，インク． 自閉症および関連障害の治療および予防のための腸管選択的隔離剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
CN103491949A (zh) * 2011-03-04 2014-01-01 株式会社吴羽 片剂型的口服给药用组合物及其制造方法
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract

Also Published As

Publication number Publication date
AU2018243836B2 (en) 2021-04-22
AU2018243836B9 (en) 2021-05-13
EP3600349A1 (en) 2020-02-05
US20180303876A1 (en) 2018-10-25
CA3095724C (en) 2023-04-18
AU2018243836A1 (en) 2019-11-21
CN110944650A (zh) 2020-03-31
KR20200024133A (ko) 2020-03-06
US11007219B2 (en) 2021-05-18
CA3095724A1 (en) 2018-10-04
US20200368276A1 (en) 2020-11-26
JP6978122B2 (ja) 2021-12-08
EP3600349A4 (en) 2020-09-30
BR112019020289A2 (pt) 2020-09-01
KR102328323B1 (ko) 2021-11-19
US20230364135A1 (en) 2023-11-16
CN114569633A (zh) 2022-06-03
JP2020513032A (ja) 2020-04-30
AU2021206871A1 (en) 2021-08-12
AU2021206871B2 (en) 2021-10-14
NZ758692A (en) 2022-03-25
CN110944650B (zh) 2022-03-04
AU2022200220A1 (en) 2022-02-10
US10617718B2 (en) 2020-04-14
US20200390809A1 (en) 2020-12-17
CA3191747A1 (en) 2018-10-04
WO2018183986A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CN114569633B (zh) 用于治疗和预防孤独症及相关障碍的肠选择性螯合剂
CN111032061A (zh) 包含细菌菌株的组合物
BR112014030835B1 (pt) Composição contendo ácido nicotínico e/ou nicotinamida e/ou triptofano, e uso da mesma
MX2012009728A (es) Formulaciones para suministro oral de adsorbentes en el intestino.
JP6554468B6 (ja) ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するための医薬組成物
CN115003318A (zh) 包含细菌菌株的组合物
TW201907927A (zh) 包含細菌菌株之組合物
CN114615971A (zh) 包含细菌菌株的组合物
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP2001158743A (ja) 乳酸菌含有組成物、医薬及び食品
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
JP2006176450A (ja) 小腸でのリンの過剰吸収を抑制可能とする乳酸菌含有組成物
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP5405793B2 (ja) 粘膜の非特異的過敏性亢進の予防又は治療剤
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
Zhu et al. Microenvironment Self‐Adaptive Nanoarmor to Address Adhesion‐and Colonization‐Related Obstacles in Impaired Intestine Promote Bacteriotherapy Against Parkinson's Disease
Di Cerbo et al. The use of probiotics in the end-stage renal disease management
Luo et al. Mechanistic Insights into a Smart Nanomotor‐Laden Inulin Hydrogel Reprogramming Gut‐Brain Axis for Combinatorial Inflammatory Bowel Disease‐Depression Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075263

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20231117

CF01 Termination of patent right due to non-payment of annual fee